Graham G. Walmsley 4
4 · Akero Therapeutics, Inc. · Filed Oct 10, 2025
Insider Transaction Report
Form 4
Graham G. Walmsley
Director
Transactions
- Exercise/Conversion
Common Stock
2025-10-08$23.02/sh+26,000$598,520→ 28,168 total - Exercise/Conversion
Common Stock
2025-10-08$25.20/sh+13,000$327,600→ 69,168 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−26,000→ 0 totalExercise: $23.02Exp: 2034-06-07→ Common Stock (26,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−13,000→ 0 totalExercise: $26.32Exp: 2031-05-31→ Common Stock (13,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−23,832→ 0 totalExercise: $19.97Exp: 2029-11-07→ Common Stock (23,832 underlying) - Exercise/Conversion
Common Stock
2025-10-08$8.13/sh+15,000$121,950→ 43,168 total - Exercise/Conversion
Common Stock
2025-10-08$26.32/sh+13,000$342,160→ 56,168 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−15,000→ 0 totalExercise: $8.13Exp: 2032-06-01→ Common Stock (15,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−13,000→ 0 totalExercise: $25.20Exp: 2030-05-31→ Common Stock (13,000 underlying) - Exercise/Conversion
Common Stock
2025-10-08$19.97/sh+23,832$475,925→ 93,000 total
Holdings
- 1,200,000(indirect: See Footnote)
Common Stock
Footnotes (2)
- [F1]The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F2]The options are vested and currently exercisable.